Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 19 | 2023 | 362 | 3.700 |
Why?
|
| Enterobacteriaceae | 8 | 2020 | 40 | 3.590 |
Why?
|
| Enterobacteriaceae Infections | 8 | 2020 | 55 | 3.540 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 10 | 2020 | 68 | 2.990 |
Why?
|
| beta-Lactamases | 11 | 2023 | 94 | 2.700 |
Why?
|
| Child | 27 | 2023 | 1153 | 2.020 |
Why?
|
| Child, Preschool | 20 | 2023 | 563 | 1.740 |
Why?
|
| Carbapenems | 5 | 2019 | 45 | 1.630 |
Why?
|
| Infant | 19 | 2021 | 478 | 1.490 |
Why?
|
| Adolescent | 20 | 2022 | 1874 | 1.410 |
Why?
|
| Bacterial Proteins | 8 | 2021 | 89 | 1.180 |
Why?
|
| Infant, Newborn | 16 | 2021 | 534 | 1.140 |
Why?
|
| Humans | 49 | 2023 | 22823 | 1.040 |
Why?
|
| Cross Infection | 4 | 2023 | 295 | 1.030 |
Why?
|
| Genotype | 2 | 2019 | 246 | 1.030 |
Why?
|
| Microbial Sensitivity Tests | 8 | 2023 | 83 | 0.970 |
Why?
|
| Plasmids | 3 | 2023 | 42 | 0.940 |
Why?
|
| Chicago | 9 | 2021 | 811 | 0.870 |
Why?
|
| Escherichia coli | 2 | 2023 | 42 | 0.850 |
Why?
|
| Klebsiella pneumoniae | 3 | 2019 | 70 | 0.820 |
Why?
|
| Fluoroquinolones | 2 | 2023 | 12 | 0.820 |
Why?
|
| Case-Control Studies | 6 | 2023 | 481 | 0.810 |
Why?
|
| Prevalence | 5 | 2020 | 375 | 0.770 |
Why?
|
| Community-Acquired Infections | 2 | 2020 | 57 | 0.770 |
Why?
|
| Endocarditis, Bacterial | 2 | 2016 | 11 | 0.760 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 2 | 2019 | 19 | 0.750 |
Why?
|
| Klebsiella Infections | 2 | 2019 | 64 | 0.700 |
Why?
|
| Staphylococcal Infections | 3 | 2015 | 156 | 0.700 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2021 | 2 | 0.700 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2021 | 3 | 0.700 |
Why?
|
| Myocarditis | 1 | 2021 | 9 | 0.690 |
Why?
|
| Gammaproteobacteria | 1 | 2021 | 3 | 0.680 |
Why?
|
| United States | 12 | 2022 | 1762 | 0.670 |
Why?
|
| Bacterial Infections | 1 | 2021 | 47 | 0.660 |
Why?
|
| Pseudomonas Infections | 2 | 2017 | 32 | 0.650 |
Why?
|
| Fresh Water | 1 | 2020 | 4 | 0.650 |
Why?
|
| Male | 20 | 2021 | 12400 | 0.640 |
Why?
|
| Acinetobacter baumannii | 1 | 2019 | 5 | 0.610 |
Why?
|
| Acinetobacter Infections | 1 | 2019 | 6 | 0.610 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2021 | 21 | 0.580 |
Why?
|
| Risk Factors | 7 | 2021 | 1966 | 0.570 |
Why?
|
| Molecular Typing | 2 | 2019 | 9 | 0.560 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2021 | 52 | 0.560 |
Why?
|
| Bacteria | 1 | 2018 | 61 | 0.550 |
Why?
|
| Ceftriaxone | 1 | 2017 | 3 | 0.520 |
Why?
|
| Evolution, Molecular | 1 | 2017 | 5 | 0.520 |
Why?
|
| beta-Lactam Resistance | 2 | 2017 | 14 | 0.510 |
Why?
|
| Raltegravir Potassium | 1 | 2016 | 2 | 0.510 |
Why?
|
| Drug Hypersensitivity Syndrome | 1 | 2016 | 3 | 0.510 |
Why?
|
| Eosinophilia | 1 | 2016 | 35 | 0.500 |
Why?
|
| Pandemics | 4 | 2021 | 201 | 0.490 |
Why?
|
| Female | 18 | 2021 | 12904 | 0.490 |
Why?
|
| Coxiella burnetii | 1 | 2016 | 3 | 0.490 |
Why?
|
| Q Fever | 1 | 2016 | 5 | 0.490 |
Why?
|
| Multilocus Sequence Typing | 4 | 2023 | 16 | 0.480 |
Why?
|
| Gingivitis, Necrotizing Ulcerative | 1 | 2015 | 1 | 0.480 |
Why?
|
| Osteosarcoma | 1 | 2015 | 36 | 0.460 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 117 | 0.420 |
Why?
|
| Enterovirus Infections | 1 | 2013 | 2 | 0.410 |
Why?
|
| Diabetes Insipidus, Neurogenic | 1 | 2013 | 3 | 0.410 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2013 | 5 | 0.410 |
Why?
|
| Meningoencephalitis | 1 | 2013 | 8 | 0.410 |
Why?
|
| Staphylococcus aureus | 1 | 2013 | 72 | 0.400 |
Why?
|
| Pneumonia, Ventilator-Associated | 3 | 2018 | 11 | 0.400 |
Why?
|
| Molecular Epidemiology | 3 | 2021 | 25 | 0.400 |
Why?
|
| Pseudomonas aeruginosa | 4 | 2020 | 40 | 0.380 |
Why?
|
| Rheumatic Fever | 1 | 2012 | 3 | 0.370 |
Why?
|
| Streptococcus pyogenes | 1 | 2012 | 4 | 0.370 |
Why?
|
| Macrolides | 1 | 2012 | 6 | 0.370 |
Why?
|
| Pharyngitis | 1 | 2012 | 7 | 0.370 |
Why?
|
| Brucella | 1 | 2011 | 3 | 0.360 |
Why?
|
| Brucellosis | 1 | 2011 | 4 | 0.360 |
Why?
|
| Delivery of Health Care | 3 | 2021 | 121 | 0.350 |
Why?
|
| Intensive Care Units | 3 | 2018 | 234 | 0.340 |
Why?
|
| Bacteremia | 1 | 2011 | 98 | 0.330 |
Why?
|
| Young Adult | 4 | 2019 | 1647 | 0.310 |
Why?
|
| DNA, Bacterial | 3 | 2019 | 37 | 0.310 |
Why?
|
| Diagnosis, Differential | 3 | 2021 | 309 | 0.300 |
Why?
|
| Tertiary Care Centers | 2 | 2019 | 63 | 0.300 |
Why?
|
| Leadership | 4 | 2021 | 78 | 0.290 |
Why?
|
| Staphylococcaceae | 1 | 2008 | 1 | 0.280 |
Why?
|
| Tuberculosis | 1 | 2007 | 18 | 0.260 |
Why?
|
| Public Health | 2 | 2018 | 47 | 0.260 |
Why?
|
| Adult | 5 | 2022 | 6896 | 0.250 |
Why?
|
| Pilot Projects | 2 | 2020 | 370 | 0.240 |
Why?
|
| Retrospective Studies | 6 | 2021 | 2976 | 0.220 |
Why?
|
| Health Facilities | 2 | 2022 | 26 | 0.220 |
Why?
|
| Personal Protective Equipment | 2 | 2021 | 10 | 0.220 |
Why?
|
| Pneumonia | 2 | 2015 | 61 | 0.210 |
Why?
|
| Phylogeny | 1 | 2023 | 44 | 0.200 |
Why?
|
| Antimicrobial Stewardship | 2 | 2020 | 17 | 0.200 |
Why?
|
| Respiration, Artificial | 3 | 2018 | 84 | 0.200 |
Why?
|
| Intensive Care Units, Pediatric | 3 | 2017 | 13 | 0.180 |
Why?
|
| Minority Groups | 1 | 2022 | 67 | 0.180 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 8 | 0.180 |
Why?
|
| Overweight | 1 | 2022 | 66 | 0.170 |
Why?
|
| Neutropenia | 1 | 2021 | 15 | 0.170 |
Why?
|
| Tachycardia | 1 | 2021 | 9 | 0.170 |
Why?
|
| Hypotension | 1 | 2021 | 20 | 0.170 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2021 | 15 | 0.170 |
Why?
|
| Logistic Models | 2 | 2019 | 350 | 0.170 |
Why?
|
| Bradycardia | 1 | 2021 | 21 | 0.170 |
Why?
|
| Mandatory Programs | 1 | 2021 | 2 | 0.170 |
Why?
|
| Federal Government | 1 | 2021 | 3 | 0.170 |
Why?
|
| State Government | 1 | 2021 | 3 | 0.170 |
Why?
|
| Local Government | 1 | 2021 | 3 | 0.170 |
Why?
|
| Masks | 1 | 2021 | 6 | 0.170 |
Why?
|
| Shock, Septic | 1 | 2021 | 25 | 0.170 |
Why?
|
| Fever | 1 | 2021 | 32 | 0.170 |
Why?
|
| Socioeconomic Factors | 1 | 2022 | 255 | 0.170 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2021 | 57 | 0.170 |
Why?
|
| Hospitals, Pediatric | 1 | 2020 | 2 | 0.170 |
Why?
|
| Clostridium Infections | 1 | 2020 | 24 | 0.170 |
Why?
|
| Candida | 1 | 2020 | 16 | 0.170 |
Why?
|
| Universal Precautions | 1 | 2020 | 6 | 0.170 |
Why?
|
| Siderophores | 1 | 2020 | 1 | 0.170 |
Why?
|
| Lactams | 1 | 2020 | 3 | 0.170 |
Why?
|
| Candidiasis | 1 | 2020 | 23 | 0.160 |
Why?
|
| Communicable Diseases | 1 | 2020 | 22 | 0.160 |
Why?
|
| Waste Disposal, Fluid | 1 | 2020 | 3 | 0.160 |
Why?
|
| Water Microbiology | 1 | 2020 | 9 | 0.160 |
Why?
|
| Survivors | 1 | 2020 | 69 | 0.160 |
Why?
|
| Escherichia coli Proteins | 1 | 2020 | 8 | 0.160 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 24 | 0.160 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 1412 | 0.160 |
Why?
|
| Cephalosporins | 1 | 2019 | 12 | 0.150 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 759 | 0.150 |
Why?
|
| Obesity | 1 | 2022 | 287 | 0.150 |
Why?
|
| Infection Control | 2 | 2022 | 168 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 74 | 0.150 |
Why?
|
| Regression Analysis | 1 | 2019 | 216 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 77 | 0.150 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2018 | 2 | 0.140 |
Why?
|
| Gram-Positive Bacteria | 1 | 2018 | 12 | 0.140 |
Why?
|
| Databases, Factual | 1 | 2019 | 307 | 0.140 |
Why?
|
| Pregnancy | 2 | 2021 | 324 | 0.140 |
Why?
|
| Animals | 5 | 2020 | 3255 | 0.140 |
Why?
|
| Greece | 1 | 2017 | 2 | 0.130 |
Why?
|
| Latin America | 1 | 2017 | 5 | 0.130 |
Why?
|
| Israel | 1 | 2017 | 11 | 0.130 |
Why?
|
| Bilirubin | 1 | 2017 | 10 | 0.130 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 22 | 0.130 |
Why?
|
| Drug Eruptions | 1 | 2016 | 8 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 54 | 0.120 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2016 | 7 | 0.120 |
Why?
|
| Antibodies, Bacterial | 1 | 2016 | 7 | 0.120 |
Why?
|
| Immunoglobulin M | 1 | 2016 | 11 | 0.120 |
Why?
|
| Ventilators, Mechanical | 1 | 2016 | 19 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 75 | 0.120 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 67 | 0.120 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2015 | 6 | 0.120 |
Why?
|
| Immunocompromised Host | 1 | 2015 | 41 | 0.120 |
Why?
|
| Hemorrhage | 1 | 2015 | 73 | 0.110 |
Why?
|
| Critical Illness | 1 | 2015 | 97 | 0.110 |
Why?
|
| ADP Ribose Transferases | 1 | 2014 | 1 | 0.110 |
Why?
|
| Bacterial Toxins | 1 | 2014 | 6 | 0.110 |
Why?
|
| Phagocytosis | 1 | 2014 | 25 | 0.110 |
Why?
|
| Enterovirus B, Human | 1 | 2013 | 2 | 0.100 |
Why?
|
| Ampicillin | 1 | 2013 | 5 | 0.100 |
Why?
|
| Pregnant Women | 1 | 2013 | 14 | 0.100 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2015 | 112 | 0.100 |
Why?
|
| Gentamicins | 1 | 2013 | 22 | 0.100 |
Why?
|
| Carrier State | 1 | 2013 | 61 | 0.100 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 11 | 0.100 |
Why?
|
| Virulence Factors | 1 | 2013 | 6 | 0.100 |
Why?
|
| Time Factors | 2 | 2013 | 1258 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2016 | 1412 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2016 | 1487 | 0.100 |
Why?
|
| Urban Population | 1 | 2013 | 127 | 0.100 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 122 | 0.100 |
Why?
|
| Hospital Mortality | 3 | 2018 | 129 | 0.090 |
Why?
|
| Ethylenediamines | 1 | 2012 | 5 | 0.090 |
Why?
|
| Penicillins | 1 | 2012 | 9 | 0.090 |
Why?
|
| Streptococcal Infections | 1 | 2012 | 9 | 0.090 |
Why?
|
| Splenomegaly | 1 | 2011 | 6 | 0.090 |
Why?
|
| Milk | 1 | 2011 | 11 | 0.090 |
Why?
|
| Mexico | 1 | 2011 | 14 | 0.090 |
Why?
|
| Hepatomegaly | 1 | 2011 | 7 | 0.090 |
Why?
|
| Travel | 1 | 2011 | 14 | 0.090 |
Why?
|
| Treatment Failure | 1 | 2012 | 126 | 0.090 |
Why?
|
| Acute Disease | 1 | 2012 | 162 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 162 | 0.090 |
Why?
|
| Recurrence | 1 | 2011 | 268 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2012 | 546 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 795 | 0.070 |
Why?
|
| Mice | 3 | 2020 | 1228 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2015 | 2934 | 0.070 |
Why?
|
| Failure to Thrive | 1 | 2007 | 1 | 0.070 |
Why?
|
| Antitubercular Agents | 1 | 2007 | 12 | 0.070 |
Why?
|
| Hospitals | 2 | 2018 | 157 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 517 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2014 | 93 | 0.050 |
Why?
|
| Child Care | 1 | 2021 | 2 | 0.040 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2021 | 9 | 0.040 |
Why?
|
| Forecasting | 1 | 2021 | 78 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2020 | 6 | 0.040 |
Why?
|
| Research | 1 | 2020 | 36 | 0.040 |
Why?
|
| Transitional Care | 1 | 2020 | 3 | 0.040 |
Why?
|
| Blood-Borne Pathogens | 1 | 2020 | 4 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 33 | 0.040 |
Why?
|
| Nursing Homes | 1 | 2020 | 41 | 0.040 |
Why?
|
| Penicillin-Binding Proteins | 1 | 2020 | 1 | 0.040 |
Why?
|
| Molecular Docking Simulation | 1 | 2020 | 2 | 0.040 |
Why?
|
| Crystallography, X-Ray | 1 | 2020 | 12 | 0.040 |
Why?
|
| Half-Life | 1 | 2020 | 11 | 0.040 |
Why?
|
| Catalytic Domain | 1 | 2020 | 12 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2020 | 55 | 0.040 |
Why?
|
| Gram-Negative Bacteria | 1 | 2020 | 26 | 0.040 |
Why?
|
| Binding Sites | 1 | 2020 | 60 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2020 | 111 | 0.040 |
Why?
|
| Inpatients | 1 | 2021 | 113 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2020 | 40 | 0.040 |
Why?
|
| Mothers | 1 | 2021 | 160 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 64 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 146 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 235 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2017 | 217 | 0.030 |
Why?
|
| Integrons | 1 | 2016 | 3 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2016 | 50 | 0.030 |
Why?
|
| Maryland | 1 | 2016 | 8 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 270 | 0.030 |
Why?
|
| Feces | 1 | 2016 | 80 | 0.030 |
Why?
|
| Length of Stay | 1 | 2016 | 298 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 102 | 0.030 |
Why?
|
| Illinois | 1 | 2015 | 221 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 56 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2015 | 172 | 0.030 |
Why?
|
| Microbial Viability | 1 | 2013 | 1 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2013 | 225 | 0.020 |
Why?
|